Literature DB >> 2050170

The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects.

D Allen1, H V Curran, M Lader.   

Abstract

The effects of a 10 day administration of clomipramine (25-50 mg t.i.d.), alprazolam (0.25-0.75 mg t.i.d.) and placebo were assessed in normal volunteers in a double-blind cross-over study. A battery of physiological, psychomotor and cognitive tests was administered both before and 3 h after drug on days 1, 5 and 10. The effects of alprazolam on EEG and evoked potentials were characteristic of benzodiazepines; clomipramine had little effect. In contrast, reaction speed was markedly slowed by clomipramine but little affected by alprazolam. Neither drug produced any accumulation of effect on a verbal recall task but neither did tolerance develop to the acute impairments produced by active treatments. Alprazolam produced an increase in levels of forgetting, especially on day 5. Subjective ratings for mood and bodily symptoms were adversely affected by clomipramine but little altered by alprazolam. It is suggested that some of the differences between drug treatments may be due to differences in the speed of onset of tolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050170     DOI: 10.1007/bf00265843

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Antidepressants in panic disorder and agoraphobia.

Authors:  R B Lydiard; J C Ballenger
Journal:  J Affect Disord       Date:  1987 Sep-Oct       Impact factor: 4.839

2.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.

Authors:  R Noyes; R L DuPont; J C Pecknold; A Rifkin; R T Rubin; R P Swinson; J C Ballenger; G D Burrows
Journal:  Arch Gen Psychiatry       Date:  1988-05

3.  Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study.

Authors:  G Chouinard; L Annable; R Fontaine; L Solyom
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Alprazolam and lorazepam effects on memory acquisition and retrieval processes.

Authors:  R I Block; R Berchou
Journal:  Pharmacol Biochem Behav       Date:  1984-02       Impact factor: 3.533

5.  Treatment of spontaneous panic attacks with chlomipramine.

Authors:  S Gloger; L Grunhaus; B Birmacher; T Troudart
Journal:  Am J Psychiatry       Date:  1981-09       Impact factor: 18.112

6.  Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged.

Authors:  R J Branconnier; D R DeVitt; J O Cole; K F Spera
Journal:  Neurobiol Aging       Date:  1982       Impact factor: 4.673

7.  Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.

Authors:  D J Greenblatt; J S Harmatz; C Dorsey; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1988-09       Impact factor: 6.875

8.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05

9.  Memory and performance effects of single and 3-week administration of diazepam.

Authors:  M M Ghoneim; S P Mewaldt; J L Berie; J V Hinrichs
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Alprazolam treatment for panic disorders.

Authors:  P E Alexander; D D Alexander
Journal:  J Clin Psychiatry       Date:  1986-06       Impact factor: 4.384

View more
  10 in total

1.  The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers.

Authors:  D Allen; H V Curran; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  The effects of alprazolam alone and combined with alcohol on central integrative activity.

Authors:  A J Bond; J C Silveira; M H Lader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests.

Authors:  A Vermeeren; J L Jackson; N D Muntjewerff; P J Quint; E M Harrison; J F O'Hanlon
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

4.  Memory and psychomotor effects of oxcarbazepine in healthy human volunteers.

Authors:  H V Curran; R Java
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  The interactions of ethanol with single and repeated doses of suriclone and diazepam on physiological and psychomotor functions in normal subjects.

Authors:  D Allen; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Cognitive effects of long-term benzodiazepine use: a meta-analysis.

Authors:  Melinda J Barker; Kenneth M Greenwood; Martin Jackson; Simon F Crowe
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Cognitive performance in depressed patients after chronic use of antidepressants.

Authors:  Clarice Gorenstein; Stefania Caldeira de Carvalho; Rinaldo Artes; Ricardo Alberto Moreno; Tania Marcourakis
Journal:  Psychopharmacology (Berl)       Date:  2006-02-17       Impact factor: 4.530

8.  Executive Functions of Obsessive Compulsive Disorder and Panic Disorder Patients in Comparison to Healty Controls.

Authors:  Emel Kurt; Erol Yildirim; Volkan Topçuoğlu
Journal:  Noro Psikiyatr Ars       Date:  2017-12       Impact factor: 1.339

9.  Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?

Authors:  Christiaan H Vinkers; Berend Olivier
Journal:  Adv Pharmacol Sci       Date:  2012-03-29

10.  The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux.

Authors:  Federica Cavaliere; Alessandra Fornarelli; Fabio Bertan; Rossella Russo; Anaïs Marsal-Cots; Luigi Antonio Morrone; Annagrazia Adornetto; Maria Tiziana Corasaniti; Daniele Bano; Giacinto Bagetta; Pierluigi Nicotera
Journal:  Sci Rep       Date:  2019-03-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.